Evidence map›Paper›PMID 41511866›Full record

ReviewThe Journal of pathology2026

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing.

Eleni Zingkou, Evangelos Bisyris, Georgios Pampalakis, Georgia Sotiropoulou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eleni ZingkouDepartment of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.ORCID https://orcid.org/0000-0001-5387-0470
Evangelos BisyrisDepartment of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.
Georgios PampalakisLaboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID https://orcid.org/0000-0002-2119-4292
Georgia SotiropoulouDepartment of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.ORCID https://orcid.org/0000-0003-0747-4914

Funding

Hellenic Foundation for Research and Innovation 16710
6 · The paper itself

Abstract

Netherton syndrome (NS) is a rare, severe, and often life-threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities. NS develops due to loss-of-function mutations in the SPINK5 gene, which encodes the LEKTI inhibitor that regulates KLK proteases (KLK5, KLK6, KLK7, KLK13, and KLK14). These findings indicate that dysregulation of proteolytic networks underlies the extensive skin shedding and inflammation characteristic of NS. Spink5

Indexed as

Netherton SyndromeAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalHumansKallikreinsMiceMice, KnockoutMutationPhenotypeProteinase Inhibitory Proteins, SecretoryProteolysisSerine Peptidase Inhibitor Kazal-Type 5KallikreinsProteinase Inhibitory Proteins, SecretorySerine Peptidase Inhibitor Kazal-Type 5SPINK5 protein, humanSpink5 protein, mousekallikrein‐related peptidases (KLKs)knockout modelsNetherton syndromeorganotypic culturesproteolytic cascadestransgenic models

Identifiers

PMID41511866
PMCPMC12908204

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.